Results 31 to 40 of about 55,621 (311)

Detection of antibodies to Sendai virus by enzyme-linked immunosorbent assay (ELISA) [PDF]

, 1979
An enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to Sendai virus, a paramyxovirus, is described. The assay was found to be about 20-fold more sensitive than the hemagglutination inhibition assay.
Avrameas, Bennink, Doherty, Doherty, Ertl, Gerhard, Hunter, Koszinowski, Koszinowski, Koszinowski, Leinikki, Lowry, Nakane, Ornstein, Roberts, Salk, Svenag, White   +17 more
core   +1 more source

Human parvovirus B19 and blood product safety. A tale of twenty years of improvements [PDF]

, 2015
Parvovirus B19 (B19V), long known to be the causative agent of erythema infectiosum (fifth disease), is not a newly emerging agent. The aim of this review is to analyse the role played by this virus in compromising safety in transfusion medicine and the ...
Calizzani, Gabriele, Candura, Fabio, Facco, Giuseppina, Grazzini, Giuliano, Liumbruno, Giancarlo M., Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +7 more
core   +1 more source

SPECIFIC IMMUNOGLOBULINS FOR INTRAVENOUS INJECTION IN PEDIATRIC PRACTICES

Педиатрическая фармакология, 2007
The article presents information on the protective and therapeutic efficiency of specific immunoglobulins for intravenous injection. The author gives a characteristics and provides regimes of medication dosage of specific immunoglobulins for intravenous ...
A.L. Zaplatnikov
doaj   +2 more sources

Diversity of IgG autoantibodies of 4 Chinese intravenous immunoglobulins

Zhongguo shuxue zazhi, 2023
Objective To develop methods to display the IgG autoantibody repertoire of intravenous immunoglobulin (IVIG) products, analyze the different types of antibodies and study the diversity of IgG autoantibody in 4 IVIG preparations from different Chinese ...
Xiaochen YAN, Li MA, Zongkui WANG, Changqing LI, Tingting LEI, Xi DU, Shengliang YE   +6 more
doaj   +1 more source

Nephrotoxicity of intravenous immunoglobulin [PDF]

QJM, 2000
Individual case reports have documented nephrotoxicity of intravenous immunoglobulin (IVIG) preparations, but the true incidence of renal dysfunction is unknown and many data sheets do not include renal impairment as a side-effect of these preparations.
J B, Levy, C D, Pusey
openaire   +2 more sources

Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition

JEADV Clinical Practice, 2022
Pyoderma gangrenosum (PG) is a rare, autoinflammatory disease leading to painful, hard‐to‐treat ulcers. Besides systemic glucocorticoids, a plethora of classic immunosuppressants, biologics and small molecules have been reported to improve PG disease ...
Sebastian Sitaru, Tilo Biedermann, Felix Lauffer   +2 more
doaj   +1 more source

Intravenous Immunoglobulin Induced Transaminitis

Cureus, 2023
Intravenous immunoglobulin (IVIG) is a common therapeutic modality used in immune-mediated neuropathy. While the therapeutic benefits are well known, adverse reactions have been reported. One such adverse event, though rare, is transaminitis, which appears to be a transient and a self-limiting adverse reaction.
Vijaya Prakash, Aviraag, Parvathaneni, Aparna, Malempati, Sarat, Keilson, Gary   +3 more
openaire   +2 more sources

HAEMAGGLUTINATION TECHNIQUES TO EVALUATE SPECIFIC SAFETY OF HUMAN INTRAVENOUS IMMUNOGLOBULINS

Медицинская иммунология, 2017
The safety issues of human intravenous immunoglobulin preparations are particularly important in modern pharmacotherapy for immunodeficiencies, hematologic and neurologic diseases, like as at transplant centers. Upon massive infusions of these media some
O. G. Kornilova, E. V. Paramonova, A. V. Nechaev, E. Yu. Kudasheva, I. V. Borisevich, N. I. Kishkurno   +5 more
doaj   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source